Showing 2771-2780 of 5909 results for "".
- Searchable Contact Lens Database Launched in U.S.https://modernod.com/news/searchable-contact-lens-database-launched-in-u-s/2478010/For the first time, the searchable contact lens database for eye care practitioners—the Contact Lens Compendium—is accessible in the United States. With the launch of the U.S. version (https://compendium.contactlensupdate.com/us), ECPs now
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu
- Ocutrx Says It Will Deliver World’s First 5G AR/XR Medical Specific Platform in 2021https://modernod.com/news/ocutrx-says-it-will-deliver-worlds-first-5g-ar-xr-medical-specific-platform-in-2021/2477980/Ocutrx Vision Technologies announced plans to deliver the first AR headsets specific for medical applications providing connectivity from AT&T and using 5G products from Qualcomm Technologies. Ocutrx is building its AR/XR medical device, the Oculenz headset, for patient use; and a seco
- Apple Was Already Developing Handwashing Sensing Before COVID-19 Hithttps://modernod.com/news/apple-was-already-developing-handwashing-sensing-before-covid-19-hit/2477981/When Apple vice president of technology Kevin Lynch announced at WWDC last week that Apple Watch would add an automatic handwashing-detection feature in its next update, many people naturally assumed the feature was prompted by the COVID-19 pandemic – a public health emergency that has strongly u
- STAAR Surgical’s EVO Viva Presbyopia Correcting Lens Receives CE Mark Approvalhttps://modernod.com/news/staar-surgicals-evo-viva-presbyopia-correcting-lens-receives-ce-mark-approval/2477977/STAAR Surgical announced that its EVO Viva presbyopia correcting implantable collamer lens (ICL) has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian ICL with Aspheric (EDOF) Optic, commercially marketed as “EVO Viva,” from its European Noti
- Nova Eye Medical Acquires Molteno3 Glaucoma Drainage Device Portfoliohttps://modernod.com/news/nova-eye-medical-acquires-molteno3-glaucoma-drainage-device-portfolio/2477974/Nova Eye Medical has completed the acquisition of ophthalmic assets from Molteno Ophthalmic Limited, including the proprietary Molteno3 glaucoma drainage device (GDD) platform. Terms of th
- Hydroxychloroquine Found to Significantly Cut Death Rates in New COVID-19 Studyhttps://modernod.com/news/hydroxychloroquine-found-to-significantly-cut-death-rates-in-new-covid-19-study/2477971/According to a large-scale retrospective analysis published in the International Journal of Infectious Diseases, hydroxychloroquine was associated with a significant decrease in death rate in patients hospitalized with COVID-19, and without heart-related side-effects. Marcus Zervos, division head
- Moderna Reiterates July Start for Phase 3 COVID-19 Vaccine Trial Following Report of Delayhttps://modernod.com/news/moderna-reiterates-july-start-for-phase-3-covid-19-vaccine-trial-following-report-of-delay/2477967/Shares in Moderna fell as much as 9.4% on Thursday after a report indicated that the company’s late-stage trial for potential COVID-19 vaccine mRNA-1273 will be delayed. According to the report in STAT News citing unnamed investigators involved in running the trial, which was slated to begin July
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorderhttps://modernod.com/news/massachusetts-eye-and-ear-enters-licensing-agreement-with-biogen-to-develop-treatment-for-inherited-retinal-disorder/2477961/Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa. Inhe
- SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophieshttps://modernod.com/news/sparingvision-receives-european-orphan-designation-for-its-drug-candidate-spvn06-dedicated-to-inherited-retinal-dystrophies/2477959/SparingVision announced the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies. The decision is based on a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).